Increased Hepatic Expression of SARS-CoV-2 Entry Points and Proinflammatory Cytokines in Cirrhosis

Rosa, Nathaly Limon‐de la; Cervantes-Álvarez, Eduardo; Navarro-Alvarez, Nalú

doi:10.1016/j.cgh.2021.08.053

Cited by 5 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Решение этого вопроса было одной из целей нашего исследования. [12,[9][10][11][12][13][14][15][16]0] 14,2 [12,[8][9][10][11][12][13][14][15][16]5] 14,9 [12,[9][10][11][12][13][14][15][16]7] 15,0 [12,[0][1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]0] 0,453 0,935 Предыдущее исследование показало, что не было существенной разницы в прогнозе между госпитализированными пациентами с циррозом пе...…”

Section: Discussionunclassified

“…-в группе не-Covid-19 (p = 0,068). Второй медицинский осмотр проводился в среднем через 8,4 [3,[1][2][3][4][5][6][7][8][9][10][11][12][13]3]…”

Section: материалы и методыunclassified

“…По данным метаанализа, изменения результатов биохимических тестов печени наблюдались почти у 50 % пациентов с COVID-19 в общей популяции и были связаны с более тяжелым течением заболевания и более высоким риском смерти [12]. Клетки печени при циррозе печени экспрессируют больше рецепторов к коронавирусу тяжелого острого респираторного синдрома 2 (SARS-CoV-2), чем нормальные клетки печени, и это более выражено при декомпенсированном циррозе печени, чем при компенсированном течении заболевания [13]. Эти рецепторы экспрессируются в больших количествах в клетках -предшественниках гепатоцитов, ответственных за регенерацию печени при циррозе печени [14].…”

Section: Introductionunclassified

See 2 more Smart Citations

Impact of Novel Coronavirus Infection on the Course and Prognosis of Cirrhosis

Ismailova,

Maslennikov,

Zharkova

et al. 2024

Rossijskij žurnal gastroènterologii, gepatologii, koloproktolog

View full text Add to dashboard Cite

Аim: to investigate the impact of COVID-19 on the course and prognosis of cirrhosis.Materials and methods. This was a cohort study in patients with cirrhosis. We included patients with cirrhosis who underwent a medical examination at our center between September 2019 and March 2020. We determined which of these patients were infected with COVID-19, died of COVID-19, or died of cirrhosis complications within the follow-up period from April 2020 to September 2021. Thereafter, we conducted a second medical examination of these surviving patients with cirrhosis in September to December 2021.Results. Among the 226 patients included in the study, 57 had COVID-19, among which 19 patients who died of the disease. Acute-on-chronic liver failure (ACLF) developed in 16 (28.1 %) patients with cirrhosis and COVID-19, 13 (81.3 %) of whom died. One of the COVID-19 survivors eventually died of liver decompensation. Twenty patients who did not have COVID-19 died of complications of cirrhosis (ACLF) during the follow-up period. The mortality rate in patients who were infected with COVID-19 was higher than that in patients who were not infected (35.1 % vs. 14.2 %; p = 0.001). COVID-19 was an independent risk factor for death in patients with cirrhosis. No liver-specific factors predisposing to COVID-19 infection were identified. A more impaired liver function in the pre-pandemic medical examination was a predisposing factor for death in patients who had COVID-19. Patients who died of COVID-19 had better liver function in the pre-pandemic medical examination than patients without COVID-19 who died of complications of cirrhosis during the follow-up period. The liver-related mortality rate and the incidence of liver decompensation or bleeding from esophageal varices during the follow-up period were not significantly different between patients who recovered from COVID-19 and patients with cirrhosis who did not have COVID-19. Among the analyzed survivors, no significant changes were found in the main indicators of liver function after the follow-up period between patients with and without COVID-19, except for the prothrombin index, which was higher in patients after COVID-19.Conclusion. COVID-19 worsens the prognosis of patients with cirrhosis but does not substantially affect the course of cirrhosis after the recovery from this infection.

show abstract

Section: Discussionunclassified

Section: материалы и методыunclassified

Section: Introductionunclassified

See 1 more Smart Citation

Impact of Novel Coronavirus Infection on the Course and Prognosis of Cirrhosis

Ismailova,

Maslennikov,

Zharkova

et al. 2024

Rossijskij žurnal gastroènterologii, gepatologii, koloproktolog

View full text Add to dashboard Cite

show abstract

“…SARS-CoV-2 обладает прямой гепатотоксичностью и проникает в печень через холангиоциты или благодаря транслокации из кишечника. Клетки печени при циррозе печени экспрессируют больше рецепторов к SARS-CoV-2, чем нормальные клетки печени [19]. Данные рецепторы экспрессируются в больших количествах в клетках -предшественниках гепатоцитов, в свою очередь отвечающих за регенерацию печени при циррозе печени [20].…”

Section: клиническое наблюдениеunclassified

Thirteen-Year Follow-Up of a Patient with Liver Cirrhosis Resulting from the Overlap Syndrome of Autoimmune Hepatitis and Primary Biliary Cholangitis: Severe COVID-19 and Liver Transplantation

Odintsova,

Akberova,

Sadykova

et al. 2024

Rossijskij žurnal gastroènterologii, gepatologii, koloproktolog

View full text Add to dashboard Cite

Aim: to present the difficulties of long-term management of a patient with liver cirrhosis in the outcome of overlap syndrome (autoimmune hepatitis and primary biliary cholangitis) who suffered from severe COVID-19 infection.Key points. The diagnosis of liver cirrhosis as an outcome of overlap syndrome (autoimmune hepatitis and primary biliary cholangitis) was established at the patient’s age of 33 years. At the age of 40, the patient became pregnant for the first time, the pregnancy proceeded well, and a cesarean section was performed at 36 weeks. At the age of 45, the patient suffered a severe new coronavirus infection, followed by decompensation of liver cirrhosis, which required liver transplantation 4 months after COVID-19, followed by a favorable postoperative course.Conclusion. This clinical case demonstrates the successful onset and outcome of pregnancy in a patient with liver cirrhosis in the outcome of overlap syndrome (autoimmune hepatitis and primary biliary cholangitis). The pronounced activity of the disease after severe new coronavirus infection required liver transplantation with successful outcome.

show abstract

“…Regardless of the nature of liver failure (direct or indirect) due to COVID-19, several possible hypotheses are believed to be linked with hepatic injury in such circumstances. Among others, the following are worth emphasizing: the direct viral effect, drug hepatotoxicity, systemic inflammatory response (cytokine storm), decompensation of pre-existing liver disease and hypoxic liver injury [58][59][60][61][62]. No pathognomonic features of hepatitis due to SARS-CoV-2 infection have been found in liver biopsy specimens.…”

Section: Certain Molecular Pathways In Covid-19-induced Liver Failurementioning

confidence: 99%

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

Michalak,

Lach,

Szczygieł

et al. 2024

IJMS

View full text Add to dashboard Cite

The pandemic period due to coronavirus disease 2019 (COVID-19) revolutionized all possible areas of global health. Significant consequences were also related to diverse extrapulmonary manifestations of this pathology. The liver was found to be a relatively common organ, beyond the respiratory tract, affected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Multiple studies revealed the essential role of chronic liver disease (CLD) in the general outcome of coronavirus infection. Present concerns in this field are related to the direct hepatic consequences caused by COVID-19 and pre-existing liver disorders as risk factors for the severe course of the infection. Which mechanism has a key role in this phenomenon—previously existing hepatic disorder or acute liver failure due to SARS-CoV-2—is still not fully clarified. Alcoholic liver disease (ALD) constitutes another not fully elucidated context of coronavirus infection. Should the toxic effects of ethanol or already developed liver cirrhosis and its consequences be perceived as a causative or triggering factor of hepatic impairment in COVID-19 patients? In the face of these discrepancies, we decided to summarize the role of the liver in the whole picture of coronavirus infection, paying special attention to ALD and focusing on the pathological pathways related to COVID-19, ethanol toxicity and liver cirrhosis.

show abstract

Increased Hepatic Expression of SARS-CoV-2 Entry Points and Proinflammatory Cytokines in Cirrhosis

Cited by 5 publications

References 11 publications

Impact of Novel Coronavirus Infection on the Course and Prognosis of Cirrhosis

Impact of Novel Coronavirus Infection on the Course and Prognosis of Cirrhosis

Thirteen-Year Follow-Up of a Patient with Liver Cirrhosis Resulting from the Overlap Syndrome of Autoimmune Hepatitis and Primary Biliary Cholangitis: Severe COVID-19 and Liver Transplantation

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

Contact Info

Product

Resources

About